Publications by authors named "Chia-Jui Yen"
Article Synopsis
- Cetuximab, a type of medicine, has been added to chemotherapy and helps patients with a serious type of throat and neck cancer to live longer.
- In this study, doctors looked at 1,434 cancer patients in Taiwan to see how well they did with cetuximab and created a risk prediction model based on their health and lifestyle factors.
- The study found that patients had an average survival time of about 8.5 months, and certain factors like how well they were able to perform daily activities and their drinking habits could affect their chances of survival.
Phase I-II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumors.
Cancer Chemother Pharmacol
December 2024
Purpose: OBI-888 is a humanized, monoclonal IgG1 antibody specific to the tumor-associated carbohydrate antigen Globo H. We conducted a phase I-II study of OBI-888 in patients with advanced cancer.
Methods: Patients were treated with OBI-888 5, 10, or 20 mg/kg IV weekly in Part A ("3 + 3" design) and 20 mg/kg IV weekly in Part B (Simon's 2-stage design) (1 cycle = 28 days).
Article Synopsis
- A study evaluated the effectiveness and safety of a new chemotherapy regimen (SOLAR) combining nab-paclitaxel, oxaliplatin, and S-1/leucovorin for treating upper gastrointestinal (UGI) cancers in patients who haven't received chemotherapy before.
- The maximal tolerated dose (MTD) for oxaliplatin was found to be 85 mg/m2, with common severe side effects being neutropenia and diarrhea.
- Preliminary results showed a promising overall response rate of 63.2%, with median progression-free survival of 12.5 months and overall survival of 24.7 months, suggesting further research is warranted.
Purpose: SHR-A1811 is an antibody-drug conjugate composed of an anti-human epidermal growth factor receptor 2 (HER2) antibody trastuzumab, a cleavable linker, and a topoisomerase I inhibitor payload. We assessed the safety, tolerability, antitumor activity, and pharmacokinetics of SHR-A1811 in heavily pretreated HER2-expressing or mutated advanced solid tumors.
Methods: This global, multi-center, first-in-human, phase I trial was conducted at 33 centers.
Article Synopsis
- - This study evaluated the safety and effectiveness of Debio 1347, a new oral drug targeting FGFR fusions in patients with advanced solid tumors, focusing on its ability to produce objective responses and other outcomes in different cancer types.
- - A total of 63 patients participated, with only a 5% objective response rate, leading to the trial's early termination due to lower-than-expected effectiveness, despite manageable side effects like hyperphosphatemia and stomatitis.
- - The findings suggest that while the drug has some tolerance, its lack of significant efficacy means it should not undergo further testing for FGFR fusion tumors; the study also provided insight into the characteristics of FGFR fusions in solid tumors.
Background/objectives: Liposomal irinotecan plus 5-fluorouracil and leucovorin (nal-IRI + 5-FU/LV) provides survival benefits for metastatic pancreatic adenocarcinoma (mPDAC) refractory to gemcitabine-based treatment, mainly gemcitabine plus nab-paclitaxel (GA), in current practice. Gemcitabine plus S-1 (GS) is another commonly administered first-line regimen before nab-paclitaxel reimbursement; however, the efficacy and safety of nal-IRI + 5-FU/LV for mPDAC after failed GS treatment has not been reported and was therefore explored in this study.
Methods: In total, 177 patients with mPDAC received first-line GS or GA treatment, followed by second-line nal-IRI + 5-FU/LV treatment (identified from a multicenter retrospective cohort in Taiwan from 2018 to 2020); 85 and 92 patients were allocated to the GS and GA groups, respectively.
Article Synopsis
- - The study investigated the connection between betel-nut chewing and PD-L1 expression in patients with recurrent/metastatic head and neck cancer in Taiwan, involving 280 mostly male participants.
- - A high prevalence of PD-L1 expression was found at 94.3%, with no significant differences in expression between those who chewed betel-nut and those who did not.
- - The results indicate that chewing betel-nut does not significantly influence PD-L1 expression rates in these cancer patients, regardless of previous treatments received.
Background: For R/M HNSCC, the differences in prognosis and treatment options between distant metastasis (DM) and locoregional recurrence, especially in the DM group, remain unclear.
Methods: From the Taiwan Head Neck Society registry database, patients who were diagnosed with R/M HNSCC and received cetuximab-based frontline therapy were collected for analysis.
Results: Among the enrolled patients, 59.
Background: Cancer susceptibility germline mutations are associated with pancreatic ductal adenocarcinoma (PDAC). However, the hereditary status of PDAC and its impact on survival is largely unknown in the Asian population.
Methods: Exome sequencing was performed on 527 blood samples from PDAC individuals and analyzed for mutations in 80 oncogenic genes.
Background: Little is known regarding the association of cetuximab treatment beyond progression (TBP) with survival among patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Although immune checkpoint inhibitors (ICIs) are now considered as first-line treatment, not all patients are suitable for ICIs.
Objective: We conducted a multicenter, retrospective study to evaluate the role of cetuximab TBP in patients with R/M HNSCC after failure of first-line cetuximab-containing chemotherapy.
Article Synopsis
- There are currently no FDA-approved therapies for nasopharyngeal carcinoma (NPC), with gemcitabine-cisplatin being the standard first-line treatment for recurrent or metastatic NPC (RM-NPC).
- The JUPITER-02 study aimed to evaluate whether the addition of toripalimab to gemcitabine-cisplatin could improve progression-free and overall survival compared to gemcitabine-cisplatin alone.
- Results showed that patients receiving toripalimab had significantly longer progression-free survival (21.4 months) and overall survival compared to those on placebo (8.2 months), indicating that toripalimab may enhance treatment outcomes for RM-NPC.
Article Synopsis
- GT90001 is an anti-ALK-1 monoclonal antibody tested for safety and effectiveness when combined with nivolumab in patients with advanced hepatocellular carcinoma (HCC).
- The study included 20 patients who experienced no significant toxicities, confirming a recommended dose of 7.0 mg/kg for GT90001, with a notable objective response rate of 30%.
- Results indicated a manageable safety profile, with encouraging anti-tumor activity, though progression-free survival was limited, averaging around 2.81 months.
Article Synopsis
- Advanced head and neck squamous cell carcinoma (HNSCC) shows a high expression level of the epidermal growth factor receptor (EGFR), which is linked to metastasis, though the role of RNA-binding proteins (RBPs) in this process is not well understood.
- This study identifies two RBPs, nucleolin (NCL) and hnRNPA2B1, as key players in promoting the mesenchymal phenotype of HNSCC and notes that reducing their levels can significantly decrease EGF-induced metastasis.
- Furthermore, the research suggests that these RBPs regulate the stability of the fibronectin mRNA through specific pathways, facilitating tumor cell attachment to blood vessels and enhancing the likelihood of metastasis, especially
Article Synopsis
- Melanoma in Taiwan is rare and primarily consists of acral and mucosal types, which differ from Western melanoma in behavior and genetics.
- Taiwanese medical experts created a local clinical practice consensus guideline to address diagnosis, staging, and treatment based on local conditions and expert evaluations.
- The guidelines emphasize surgical management (especially sentinel lymph node biopsies), require BRAF molecular testing before systemic treatment, and prioritize immunotherapy and targeted therapy for patients.
Background: Hepatitis B virus (HBV)-encoded X antigen, HBx, assists in the development of hepatocellular carcinoma (HCC) through complex mechanisms. Our results provide new insights into the EZH2 epigenetic repression of let-7c that promotes HCC migration induced by HBx. Thus, let-7c and HMGA2 represent key diagnostic markers and potential therapeutic targets for the treatment of HBV-related HCC.
View Article and Find Full Text PDFAlthough human pluripotent stem cells (hPSCs)-derived cardiomyocytes (hPSC-CMs) can remuscularize infarcted hearts and restore post-infarct cardiac function, post-transplant rejection resulting from human leukocyte antigen (HLA) mismatching is an enormous obstacle. It is crucial to identify hypoimmunogenic hPSCs for allogeneic cell therapy. This study is conducted to demonstrate the immune privilege of HLA-E /HLA-G /HLA-II human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes (hiPSC-CMs).
View Article and Find Full Text PDFBackground: Gastrectomy remains the curative option in gastric cancer. However, the growing concern that preoperative waiting jeopardizes survival has not been fully addressed. The present population-based cohort study aimed to clarify the impact of preoperative waiting time (PreWT).
View Article and Find Full Text PDFBackground: Patients with locally advanced esophageal squamous cell carcinoma (ESCC) following neoadjuvant chemoradiotherapy (nCRT) may not always receive resection despite the possible achievement of a pathologic complete response (pCR) being associated with superior survival benefit. We aimed to compare outcomes among ESCC patients with or without pCR and those refusing surgery.
Methods: In total, 111 medically operable, non-cervical ESCC patients after the same protocol of nCRT (platinum/5-fluorouracil plus radiation 50Gy) were prospectively enrolled between 2011 and 2021.
Background: RET plays an oncogenic role, and its aberrations are potentially actionable. However, they have seldom been reported in tumours other than lung or thyroid cancers. The correlation of RET aberrations with clinical characteristics, co-occurring aberrations, and responses to immune checkpoint inhibitors (ICPi) have not been explored in digestive tract tumours.
View Article and Find Full Text PDFArticle Synopsis
- Tislelizumab, an antibody targeting the PD-1 protein, showed some effectiveness and safety for treating advanced hepatocellular carcinoma (HCC) in patients who had received prior therapies.
- In a phase 2 study involving 249 patients, the objective response rate (ORR) was 13%, with a disease control rate of 53% and a median overall survival of 13.2 months.
- Side effects were mostly manageable, with only 15% of patients experiencing severe treatment-related adverse events, and no treatment-related deaths reported.
Background: The nomogram derived from the pivotal phase III NAPOLI-1 study demonstrated a significant ability to predict median overall survival (OS) in gemcitabine-refractory metastatic pancreatic ductal adenocarcinoma (PDAC) treated with liposomal irinotecan plus fluorouracil and leucovorin (nal-IRI+5-FU/LV). However, the NAPOLI-1 nomogram has not been validated in a real-world setting and therefore the applicability of the NAPOLI-1 nomogram in daily practice remains unknown. This study aims to evaluate the NAPOLI-1 nomogram in a multicenter real-world cohort.
View Article and Find Full Text PDFArticle Synopsis
- Liposomal irinotecan (nal-IRI) combined with 5-fluorouracil and leucovorin shows improved survival for pancreatic ductal adenocarcinoma (PDAC) patients after they progress from gemcitabine therapy.
- A study of 667 patients analyzed the effects of starting doses and escalation of nal-IRI on survival and toxicity, categorizing them into standard and reduced doses with or without escalation.
- Results indicated that patients with reduced doses followed by escalation had the longest treatment cycles and better overall survival compared to those on standard doses or reduced doses without escalation, although standard doses resulted in higher rates of severe side effects.
Background: Sorafenib (SOR) is the first line treatment for advanced hepatocellular carcinoma (HCC), but resistance develops frequently. Tumor-associated macrophages (TAMs) have been reported to affect the progression of HCC. We therefore aimed to study the role of TAMs in promoting SOR resistance.
View Article and Find Full Text PDFBackground: Hepatocellular carcinoma (HCC) patients suffer varying degrees of heart dysfunction after tyrosine kinase inhibitor (TKI) treatment. Interestingly, HCC patients often have higher levels of pentraxin 3 (PTX3), and PTX3 inhibition was found to improve left ventricular dysfunction in animal models.
Objectives: We sought to assess the therapeutic potential of PTX3 inhibition on TKI-associated cardiotoxicity.